Request Demo

Last update 30 Aug 2025

Fentanyl

Last update 30 Aug 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryFentanyl is a synthetic opioid that is highly effective in the management of severe pain, especially in cancer patients. It exerts its analgesic effects by binding to opioid receptors in the central nervous system. Fentanyl is available in various formulations, including transdermal patches, lozenges, and injectable solutions. However, due to its potency, fentanyl carries a high risk of addiction, respiratory depression, and overdose. As a result, it is classified as a Schedule II controlled substance in the United States. Ongoing research is focused on developing safer and more effective delivery methods for fentanyl, such as abuse-deterrent formulations and novel routes of administration.

Drug Type

Small molecule drug

Synonyms

AeroLEF, Fentany Transdermal System, Fentanyl (JAN/USP/INN)

+ [38]

Target

Opioid receptors

Action

agonists

Mechanism

Opioid receptors agonists(Opioid receptors agonists)

Therapeutic Areas

Nervous System DiseasesOther DiseasesNeoplasms

Active Indication

Cancer PainChronic PainPain+ [4]

Inactive Indication

Acute PainAdvanced cancerBreakthrough Pain+ [11]

Originator Organization

Janssen Global Services LLC

Active Organization

Medrx Co., Ltd.

Zhaoke Pharmaceutical (Guangzhou) Ltd.Janssen Pharmaceutical KK

+ [6]

Inactive Organization

Janssen Pharmaceuticals, Inc.

INSYS Therapeutics, Inc.

ALZA Corp.

+ [4]

License Organization

Terumo Corp. /Hemodialyzer Marketing Operations/

Nutriband, Inc.

Kindeva Drug Delivery LP

+ [4]

Drug Highest PhaseApproved

First Approval Date

United States (07 Aug 1990),

HypoventilationPain, Postoperative

Regulation-

Structure/Sequence

Molecular FormulaC22H28N2O

InChIKeyPJMPHNIQZUBGLI-UHFFFAOYSA-N

CAS Registry437-38-7

810

Clinical Trials associated with Fentanyl

NCT07076368

/ Not yet recruitingPhase 3IIT

Determination of the 90% Effective Volume (ED90) of Epidural 0.1% Ropivacaine and Fentanyl for Labor Analgesia Initiation in Patients Receiving a Dural-Puncture Epidural Technique

This study is being done to determine the most effective dose of medicine to use to initially provide effective pain relief within the first 30 minutes of receiving an epidural for pain labor during labor. The study team will also study any side effects related to the epidural medication and patients' satisfaction with the quality of pain relief after receiving the epidural.

Start Date31 Aug 2025

Sponsor / Collaborator

The University of California, San Francisco

NCT06953453

/ Not yet recruitingPhase 1

A Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Malignant Tumors

This study is a single-dose, open-label, 2-cycle crossover design, comparing the pharmacokinetic parameters and safety of Inhaled Fentanyl Aerosol and intravenous fentanyl injection.

Start Date30 Aug 2025

Sponsor / Collaborator

Lee's Pharmaceutical Holdings Ltd.

NCT07144410

/ Active, not recruitingNot ApplicableIIT

Balancing Analgesia and Side Effects: Intrathecal Fentanyl and Morphine Versus Fentanyl for Cesarean Section Anesthesia

Intrathecal opioids are frequently combined with local anesthetics to optimize spinal anesthesia for cesarean delivery. Fentanyl, a lipophilic opioid, offers rapid onset and enhanced intraoperative analgesia. However, its postoperative analgesic duration is limited, but in contrast, morphine, a hydrophilic opioid, provides prolonged postoperative pain control but has a slower onset and a higher incidence of adverse effects, notably nausea and vomiting. This prospective, randomized, double-blind, parallel study enrolled 180 parturients scheduled for elective cesarean section, all receiving spinal anesthesia with hyperbaric bupivacaine (7.5-10 mg, adjusted to height) plus either intrathecal fentanyl 25 µg (F group) or intrathecal morphine 100 µg and fentanyl 25µg (M+F group). Primary outcomes include intraoperative and postoperative pain scores, systemic opioid consumption, and patient satisfaction, while secondary outcomes assess the incidence of opioid-related side effects.

Start Date01 Aug 2025

Sponsor / Collaborator

University of Oradea

100 Clinical Results associated with Fentanyl

100 Translational Medicine associated with Fentanyl

100 Patents (Medical) associated with Fentanyl

26,929

Literatures (Medical) associated with Fentanyl

31 Dec 2025·ANNALS OF MEDICINE

Respiratory depression in women receiving propofol/esketamine versus propofol/fentanyl for abortion surgery or curettage: a randomized clinical trial

Article

Author: Chen, Huihe ; Guan, Xuehai ; Luo, Jiaxin ; Wu, Xiaoshan ; Cao, Huiyu ; Lan, Hongmeng ; Lin, Yuliu ; Zhang, Cuiwen ; Liao, Yeqing ; Huang, Xiaofang

BACKGROUND:

A combination of opioids with propofol is a popular approach to non-intubated general anaesthesia; however, this method usually results in higher incidence of respiratory depression. We compared the incidence of esketamine- and fentanyl-induced respiratory depression in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia.

METHODS:

This study included 176 women (aged 18-60 years) scheduled for abortion surgery or curettage. Patients were randomized into the fentanyl or esketamine groups. Patients in the fentanyl group received fentanyl (1 µg/kg) combined with propofol intravenously. Patients in the esketamine group received subanaesthetic doses of esketamine (0.15 mg/kg) combined with propofol intravenously. The primary outcome was the incidence of respiratory depression during anaesthesia. Secondary outcomes included respiratory rate, pulse oximetry, blood pressure, heart rate, propofol dose, duration of surgery, duration of anaesthesia, and adverse events.

RESULTS:

The incidence of respiratory depression in the esketamine group was significantly lower than that in the fentanyl group (11% vs. 45%; p < .0001). Propofol administration was lower with esketamine than fentanyl. Respiratory rate, SpO₂ and blood pressure were more stable in the esketamine group than in the fentanyl group. The incidences of hypotension, propofol-induced injection pain and chin lifting in the esketamine group were lower than those in the fentanyl group. The incidence of nightmares was higher in the esketamine than in the fentanyl group.

CONCLUSIONS:

The incidence of respiratory depression was lower with subanaesthetic doses of esketamine than with fentanyl in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia.KEY MESSAGESOpioids combined with propofol is a popular method for non-intubated general anaesthesia; however, this method usually results in higher incidence of respiratory depression.At subanaesthetic doses, esketamine provides an analgesic effect by antagonizing the N-methyl-d-aspartate receptor.In this trial, the incidence of respiratory depression was lower with subanaesthetic doses of esketamine than with fentanyl in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia.

31 Dec 2025·ANNALS OF MEDICINE

Liposomal bupivacaine vs. Ropivacaine for wound infiltration on chronic postsurgical pain after video-assisted thoracoscopic lung surgery: protocol for a randomized, double-blind, controlled trial

Article

Author: Zhao, Han-xue ; Chen, Shao-mu ; Shan, Xi-sheng ; Ji, Fu-hai ; Meng, Xin-tong ; Peng, Ke ; Shi, Yi-fan ; Dou, Wei

INTRODUCTION:

Chronic postsurgical pain (CPSP) remains a significant challenge for patients undergoing video-assisted thoracoscopic surgery (VATS), compromising their quality of life and postoperative recovery. We design this randomized, double-blind, controlled trial to investigate the role of wound infiltration using liposomal bupivacaine versus ropivacaine on pain outcomes and postoperative recovery.

PATIENTS AND METHODS:

A total of 180 adult patients scheduled to undergo VATS procedures for lung resection will be enrolled. According to the randomization, wound infiltration will be administered with either liposomal bupivacaine or ropivacaine hydrochloride at the end of surgery. Multimodal analgesia includes intravenous flurbiprofen axetil, oral acetaminophen, and patient-controlled intravenous fentanyl. Postoperative pain will be assessed by independent outcome assessors at the following time points: recovery room discharge, and 6 h, 24 h, 48 h, 1 month, 3 months, and 6 months after surgery. The primary outcome is the incidence of CPSP at 3 months. Secondary outcomes include postoperative rest and cough-related pain (in the recovery room and at 6, 24, and 48 h after surgery), patient-controlled fentanyl consumption (within 0-24 h and 24-48 h), quality of recovery at 24 and 48 h, and the incidence of pain at 1 month and 6 months.

DISCUSSION:

Our findings will provide evidence on the use of liposomal bupivacaine for postoperative analgesia in patients undergoing VATS lung procedures. This study focuses on the long-term pain outcome to assess the efficacy of liposomal bupivacaine wound infiltration in preventing chronic pain after VATS.

TRIAL REGISTRATION:

Chinese Clinical Trial Register (ChiCTR2400091157).

01 Nov 2025·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Urgent need for reversal agents for xylazine and other imidazolines in illicit fentanyl

Article

Author: Seger, Donna L ; Mullins, Michael E

The epidemic of illicit fentanyl use continues in the United States. Xylazine, a veterinary tranquilizer closely related to clonidine, is now a widespread adulterant in illicit fentanyl. More recently medetomidine (racemic version of dexmedetomidine) has appeared with increasing frequency in the fentanyl supply. Specific reversal agents for xylazine and medetomidine such as atipamezole and tolazoline have decades of approved use in animals and favorable experimental use in humans. However, an expert panel in 2024 opined that research into human use of alpha-adrenergic agonist was neither "necessary nor worthwhile". We disagree. We outline the unmet need for reversal agents for xylazine and medetomidine, discuss their human evidence of effectiveness, and suggest the path forward as the fentanyl epidemic continues to evolve.

405

News (Medical) associated with Fentanyl

29 Aug 2025

·www.globenewswire.com

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

Pro Football Hall of Famer and Ready to Rescue campaign spokesperson, Emmitt Smith, and Release Recovery Founder/CEO, Zac Clark, plan to visit several U.S. college campuses to educate on opioid emergency preparednessNew sponsorship of Mobilize Recovery's “Campus Surge” initiative brings addiction prevention and recovery support to higher education institutions GAITHERSBURG, Md., Aug. 29, 2025 (GLOBE NEWSWIRE) -- In honor of International Overdose Awareness Day (IOAD) on August 31, Emergent BioSolutions (NYSE: EBS) is re-launching its Ready to Rescue public education campaign, which raises awareness of opioid emergencies and the importance of being prepared with NARCAN® Nasal Spray among young adults at college/university activations with Greek Life, wellness services and athletic departments. Together, Pro Football Hall of Famer and campaign spokesperson, Emmitt Smith, and Release Recovery founder and CEO, Zac Clark will lead inspiring conversations to break down the stigma around accidental opioid poisonings and empower students to be ready to save a life with over-the-counter NARCAN® Nasal Spray. Despite encouraging data showing a decline in overdose deaths in 2024,i the dangers of the opioid crisis remain ever present. A recent report from Mental Health America analyzing publicly available national data shows that progress in reducing overdose deaths is not uniform across the country, with some states differing significantly on prevention strategies and overdose reduction. The report provides a comprehensive ranking of opioid overdose responses across every state, analyzing four systems that have the greatest potential for impact including public health, healthcare, schools and jails. The new report identifies Texas, Illinois, Louisiana and Michigan as states in need of the most opioid overdose response support in at least one system. This fall, Ready to Rescue will host a tailgate activation at schools near Chicago, IL, and will be joined by Release U – Release Recovery’s digital personal development and mental wellness platform designed to meet the needs of today's students in Dallas, TX, Baton Rouge, LA and Detroit/Ann Arbor, MI. In light of the rise of synthetic opioids, like fentanyl, paired with potential stressors that many students face,ii Smith and Clark will discuss the connection between mental health and substance use, while encouraging students to look out for each other by normalizing these topics. During the events, attendees will also receive Ready to Rescue kits with information on the signs of an opioid emergency and watch NARCAN® Nasal Spray demonstrations, so they can be prepared to save a life using the simple “Lay, Spray, Stay” method. "Having personally navigated the profound challenges of opioid dependency after brain surgery and supported so many truly incredible people on their sobriety journeys at Release Recovery, I know that opioid emergencies can happen to anyone, anywhere, at any time,” said Zac Clark, founder & CEO of Release Recovery. “I’m proud to be teaming up with Emergent for these campus events to extend critical naloxone resources that will help the next generation be better prepared in an opioid emergency. Every conversation is an important step in changing the course of the epidemic, and ultimately, saving lives.” Opioid misuse and dependency is the highest among young adults ages 18 to 25,iii yet less than 15 percent of American college students know how to administer live-saving opioid reversal naloxone medications.iv In honor of IOAD’s focus on overdose prevention and to help close this gap, Emergent is also sponsoring Mobilize Recovery’s Campus Surge initiative, which will provide action-driven overdose education and harm reduction engagement across several additional college campuses nationwide. This year, Campus Surge will provide life-saving resources and prevention tools to schools at the start of the academic year to empower students to activate change. “On International Overdose Awareness Day and every day, Emergent honors the countless lives lost from opioid overdoses, and is committed to leading and strengthening our efforts across the U.S. and Canada to help reduce the devastating toll of this public health crisis," said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “Our mission is to protect and save lives – and that is fulfilled when we positively impact at-risk and vulnerable communities, like college students, while also ensuring widespread access and awareness of over-the-counter NARCAN® Nasal Spray 4 mg, so more people can be ready to rescue when it matters most.” Recognizing the signs of an opioid overdose/poisoning—such as trouble breathing, pinpoint pupils, and pale and clammy skin—and acting quickly can be the difference between successfully reversing the effects of a poisoning, and not.v Visit ReadytoRescue.com for additional education and resources, and to learn how to be prepared in an opioid overdose emergency with life-saving intranasal naloxone visit NARCAN.com (U.S. site) and NARCANNasalSpray.ca (Canada site). Emmitt Smith and Zac Clark are paid spokespeople for Emergent. About NARCAN® Nasal Spray NARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed. About Emergent BioSolutions At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. Investor Contact: Richard S. Lindahl Executive Vice President, CFO lindahlr@ebsi.com Media Contact: Assal Hellmer Vice President, Communications mediarelations@ebsi.com _____________________________ i https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2025/20250514.htmii https://americanaddictioncenters.org/rehab-guide/collegeiii https://pmc.ncbi.nlm.nih.gov/articles/PMC8750763/iv https://pubmed.ncbi.nlm.nih.gov/38648053/v Product Monograph. 2025. NARCAN® Nasal Spray. Retrieved from https://narcannasalspray.ca/PM/NNS_EN.pdf.

Drug Approval

21 Aug 2025

·www.globenewswire.com

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

GAITHERSBURG, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- As opioid emergencies continue to be the leading cause of accidental death in the United States,1 Emergent BioSolutions (NYSE: EBS) is teaming up with Voices for Awareness and Facing Fentanyl Now in honor of National Fentanyl Prevention and Awareness Day™ on August 21, 2025. As part of this year’s efforts, these leading advocacy organizations and its sponsors will bring their message to Times Square, NYC on the day with several high-visibility billboards that expose fentanyl risks and urge a nationwide call to action to reduce the stigma around opioid poisonings ensuring that more people can be prepared to save a life. Synthetic opioids, such as fentanyl, are a key driver of the opioid epidemic, contributing to nearly 70 percent of all overdose deaths.2 Its undetectable nature—lacking taste, smell, or visible characteristics—makes fentanyl particularly dangerous, and this partnership underscores a shared commitment to saving lives through increased public awareness. National Fentanyl Prevention and Awareness Day™, observed nationwide and recognized by the U.S. Senate, serves as a critical platform to bring together families, community leaders, law enforcement, and federal agencies to combat the devastating impact of the fentanyl crisis. In memory of the countless lives lost to opioid poisonings, the day focuses on distributing life-saving naloxone, sharing vital opioid overdose prevention education and amplifying messages designed to protect communities from illicit fentanyl. “We’re proud to sponsor Voices for Awareness and Facing Fentanyl Now on National Fentanyl Prevention and Awareness Day™ to help provide much-needed awareness about fentanyl risks and life-saving tools like naloxone nasal spray,” states Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “Sadly, we are still losing far too many lives each day from opioid overdoses – this includes counterfeit pills that contain deadly fentanyl – so we must continue to educate the public on the signs of an opioid emergency and the importance of carrying naloxone.” In light of the large number of opioid overdose fatalities in recent years,3 Emergent has remained committed to educating the public through its Ready to Rescue initiative. The campaign is focused on combating misinformation surrounding opioid poisonings and empowering the public to make the socially responsible decision to carry over-the-counter naloxone because opioid emergencies can happen to anyone, anywhere, at any time. Emergent will continue to identify pathways to expand access to multiple forms of naloxone, including over-the-counter NARCAN® Nasal Spray 4 mg and prescription KLOXXADO® Nasal Spray 8 mg to help ensure that every state, business, university and household is prepared to save a life. For more information about National Fentanyl Prevention and Awareness Day™ and how to get involved, visit FacingFentanylNow.com or VoicesforAwareness.com. To learn how to be prepared in an opioid emergency with life-saving intranasal naloxone, visit NARCAN.com or KLOXXADO.com. About NARCAN® Nasal SprayNARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed. Important Safety Information for KLOXXADO® (naloxone HCl) Nasal Spray 8 mgWhat is KLOXXADO® Nasal Spray? KLOXXADO® Nasal Spray is a prescription medicine used for the treatment of an opioid emergency such as an overdose or a possible opioid overdose in adults and children with signs of breathing problems and severe sleepiness or not being able to respond.KLOXXADO® Nasal Spray is to be given right away and does not take the place of emergency medical care.Get emergency medical help right away after giving the first dose of KLOXXADO® Nasal Spray, even if the person wakes up. What is the most important information I should know about KLOXXADO® Nasal Spray?Get emergency medical help right away after giving the first dose of KLOXXADO® Nasal Spray. The signs and symptoms of an opioid emergency can return after KLOXXADO® Nasal Spray is given. If this happens, give another dose after 2 to 3 minutes using a new KLOXXADO® Nasal Spray and watch the person closely until emergency help is received. The medicine in KLOXXADO® Nasal Spray is safe to use in people who are not taking opioids. KLOXXADO® Nasal Spray is not intended for self-administration. What should I tell my healthcare provider (pharmacist or prescriber) before using KLOXXADO® Nasal Spray?Before using KLOXXADO® Nasal Spray, tell your healthcare provider about all of your medical conditions, including if you: have heart problemsare pregnant or plan to become pregnant. Use of KLOXXADO® Nasal Spray may cause withdrawal symptoms in your unborn baby. Your unborn baby should be examined by a healthcare provider right away after you use KLOXXADO® Nasal Spray.are breastfeeding or plan to breastfeed. It is not known if KLOXXADO® Nasal Spray passes into your breast milk. What are the possible side effects of KLOXXADO® Nasal Spray?KLOXXADO® Nasal Spray may cause severe opioid withdrawal symptoms including body aches, diarrhea, increased heart rate, fever, runny nose, sneezing, goose bumps, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, stomach cramping, weakness, and increased blood pressure. In infants under 4 weeks old who have been receiving opioids regularly, sudden opioid withdrawal may be life-threatening if not treated the right way. Signs and symptoms include seizures, crying more than usual, and increased reflexes. Who should not use KLOXXADO® Nasal Spray?Do not use KLOXXADO® Nasal Spray if you are allergic to naloxone hydrochloride or any of the ingredients in KLOXXADO® Nasal Spray. What are the most common side effects of KLOXXADO® nasal spray?The most common side effects of KLOXXADO® Nasal Spray in adults include stomach-area (abdomen) pain, weakness, dizziness, headache, nose (nasal) discomfort, and a feeling like you are going to faint. These are not all of the possible side effects of KLOXXADO® Nasal Spray. Please see full Prescribing Information, including Patient Information, which includes a more complete discussion of the risks associated with KLOXXADO® Nasal Spray. Always contact your healthcare provider (pharmacist or prescriber) if you have questions or experience any side effects. You are encouraged to report negative side effects to the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch. You can also contact Hikma Specialty USA Inc. at: us.hikma@primevigilance.com or call 1-877-845-0689 or 1-800-962-8364. Trademarks and logos are the property of their respective owners. About Emergent BioSolutions At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. Investor Contact:Richard S. LindahlExecutive Vice President, CFOlindahlr@ebsi.com Media Contact:Assal HellmerVice President, Communicationsmediarelations@ebsi.com ___________________1 https://injuryfacts.nsc.org/all-injuries/preventable-death-overview/odds-of-dying/2 https://www.cdc.gov/stop-overdose/caring/fentanyl-facts.html3 https://www.kff.org/mental-health/issue-brief/opioid-deaths-fell-in-mid-2023-but-progress-is-uneven-and-future-trends-are-uncertain/

Drug Approval

19 Aug 2025

·www.prnewswire.com

Biolabs International's New App Cuts Clinic Visits, Expands Testing Access

Biolabs' CONNECTED DIAGNOSTICS App and decentralized clinical trial platform integrates rapid diagnostic testing, artificial intelligence, and telehealth, all accessible from a smartphone SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Biolabs International LLC, a healthcare innovation company based in San Diego, California, is transforming how diagnostics are delivered and accessed , both in the home and in clinical research. Through the rollout of its CONNECTED DIAGNOSTICS App and decentralized clinical trial platform, Biolabs is eliminating unnecessary doctor visits, reducing barriers to care, setting new standards for accessible, AI-powered healthcare and facilitating the FDA registration and approval process for future diagnostic tools. Continue Reading SpeedySwab 3-in-1 COVID + Flu A & B test with telehealth SpeedySwab telehealth app user interface showing virtual COVID-19 test, and video consultation features on a smartphone screen Powder TracerPowderTracer™ rapid surface drug detection kit for fentanyl, cocaine, methamphetamine, and other substances, with AI-assisted app for law enforcement and emergency responders PowderTracer 7-in-1 surface drug test kit with mobile app interface for instant detection results of substances like cocaine, fentanyl, and methamphetamine

Diagnostic Reagents

100 Deals associated with Fentanyl

External Link

KEGG	Wiki	ATC	Drug Bank
D00320	Fentanyl	N02AB03 N01AH01	DB00813

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cancer Pain	Japan	Janssen Pharmaceutical KK	01 Feb 2011
Pain	Australia	Janssen-Cilag Pty Ltd.	23 Nov 2005
Acute Pain	United States	Janssen Pharmaceuticals, Inc.	04 Feb 2005
Chronic Pain	United States	Janssen Pharmaceuticals, Inc.	04 Feb 2005
Hypoventilation	United States	Janssen Pharmaceuticals, Inc.	07 Aug 1990
Pain, Postoperative	United States	Janssen Pharmaceuticals, Inc.	07 Aug 1990

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mucositis	Phase 3	United States	INSYS Therapeutics, Inc.	01 Oct 2009
Solid tumor	Phase 3	United States	INSYS Therapeutics, Inc.	01 Oct 2009
Stomatitis	Phase 3	United States	INSYS Therapeutics, Inc.	01 Oct 2009
Low Back Pain	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Jan 2009
Osteoarthritis	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Jan 2009
Complex Regional Pain Syndromes	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Dec 2008
Neuralgia, Postherpetic	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Dec 2008
Pain Disorder	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Dec 2008
Neoplasms	Phase 3	Canada	INSYS Therapeutics, Inc.	01 Dec 2007
Neoplasms	Phase 3	India	INSYS Therapeutics, Inc.	01 Dec 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03434678 (CTgov)	Phase 3	Pancreatic Cancer	133	Open Pancreaticoduodenectomy+Propofol+Fentanyl Inhalational Agent+Rocuronium+Bupivacaine (Epidural-General Anesthesia)	lrrcegolxa = dfxocmnmha imqotjbhvz (jfzmtjhkwy, eoobshrfns - omanqpzhql) View more	-	30 Jul 2025
				Open Pancreaticoduodenectomy+Propofol+Fentanyl+Rocuronium (General Anesthesia)	lrrcegolxa = aulintyiac imqotjbhvz (jfzmtjhkwy, bfkoffgvnb - qprdusmcvt) View more
ASH2024	Not Applicable	Acute Pain \| Anemia, Sickle Cell	-	Intranasal Fentanyl (INF)	rzmklzdppq(jrkotfwywk) = 7 (18%) of visits mhxyjmwoua (yhfkqumadm ) View more	-	08 Dec 2024
NCT05244226 (CTgov)	Phase 2	Sleep Apnea, Obstructive \| Tonsillitis \| Pain, Procedural	66	Hydromorphone+Fentanyl	bglubtyodp(azhieozwys) = xvrtwuwvnd qlalplqhho (jpcnzdvnmu, uhsnrmhlvq - vudkduvobu) View more	-	17 Oct 2024
NCT03872700 (CTgov)	Phase 3	Abscess	49	Intranasal fentanyl (Intranasal Fentanyl)	neasxodnfe(gbmousxfyv) = inkrysostv xzuvtpcwoo (vtblfkotiw, 1.5) View more	-	15 Aug 2023
				Placebo (Placebo)	neasxodnfe(gbmousxfyv) = pjzonjhzyf xzuvtpcwoo (vtblfkotiw, 2.9) View more
ICML2023	Not Applicable	18 FDG	-	Fentanyl pre-treatment	wcoewczror(dyxiuyennk) = enrknxnevr rovrwbzwlk (svvpekupyf )	Positive	09 Jun 2023
				No fentanyl pre-treatment	wcoewczror(dyxiuyennk) = rshjczhxfv rovrwbzwlk (svvpekupyf )
NCT00580489 (CTgov)	Not Applicable	Pain \| Drug-Related Side Effects and Adverse Reactions	204	fentanyl+morphine (Arm C Morphine)	ztdlicpfcd = fgfwijzhpn rdbzljeqbj (soaenhpaja, daevkitqpl - iyxwzlokpa)	-	16 Aug 2022
				fentanyl+morphine (Arm D Fentanyl)	ztdlicpfcd = ujsjnnfrln rdbzljeqbj (soaenhpaja, cguurcpppp - skkjtlnnww)
NCT03776838 (NOLGYN, Pubmed \| Anaesth Crit Care Pain Med)	Phase 4	-	70	NOL-guided administration of fentanyl	ojdkeasxvj(qdwnhbiddz) = kvayfwjncn socmswimls (skskfvewja, 99.9 - 113.4)	Positive	25 May 2022
				intravenous fentanyl (Standardized care)	ojdkeasxvj(qdwnhbiddz) = zzganptwhv socmswimls (skskfvewja, 97.5 - 110.7)
NCT03792191 (CTgov)	Not Applicable	Anesthesia \| Obesity	280	Lumbar Spinal Ultrasonography+Intrathecal Fentanyl+Intrathecal Bupivacaine (Ultrasonography)	agzrmmkjke(qnqfeugplc) = sycwivbglu wumsszrkms (vrxirutjus, dviszbizts - lkwumcuojk) View more	-	24 May 2021
				Conventional Landmark Palpation+Intrathecal Fentanyl+Intrathecal Bupivacaine (Palpation)	agzrmmkjke(qnqfeugplc) = uzoanjqnrq wumsszrkms (vrxirutjus, vulvjmnuha - kwjrylmthe) View more
NCT02514252 (CTgov)	Phase 2	Breakthrough Pain \| Advanced cancer	6	Study Diary+Fentanyl	sfvjsjdezd(hoxztxkday) = jwmrvparud izrxzfjcgd (fmitdpuwao, xucwjuvrqk - cxwakutewo) View more	-	18 May 2021
NCT02597478 (CTgov)	Phase 2/3	Neoplasms	50	Fentanyl (Intervention Group (High Dose Fentanyl Sublingual Spray))	slpquhrcni(spyoboqngb) = kvcmvhslzh tweiaxbofk (sucsongrrq, iyxjewzhtl - qbkgfgalsx) View more	-	08 Dec 2020
				Fentanyl (Controlled Group (Low Dose Fentanyl Sublingual Spray))	slpquhrcni(spyoboqngb) = hengkcmajj tweiaxbofk (sucsongrrq, ratkmelodq - btagukcrvo) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis